Trevi Therapeutics, Inc. (TRVI) Stock Analysis

Trevi Therapeutics' entire clinical and commercial strategy rests on Haduvio, an oral extended-release nalbuphine formulation and the company's sole product candidate, which met its primary endpoint in the Phase 2b CORAL trial for IPF-related chronic cough in June 2025, reducing 24-hour cough frequency by up to 60.2% versus a 16.9% placebo reduction in a trial conducted at sites across ten countries. The company also reported positive Phase 2a RIVER trial results in March 2025 for refractory chronic cough, a 67% cough-frequency reduction versus 10% for placebo, and plans to initiate two parallel Phase 3 trials for IPF-related cough in the second quarter and second half of 2026.

Trevi has no approved products and no product revenue, funding Haduvio's development through equity and debt financings while retaining worldwide commercialization rights rather than licensing them to a partner. The company built its clinical program on nalbuphine's decades-long safety record as an approved injectable pain treatment, marketed generically as Nubain, and on eight prior Haduvio trials, including two Phase 2 pain studies, licensed from Keenova Therapeutics, the successor to original developer Penwest Pharmaceuticals following mergers into Endo and then Mallinckrodt. Under that license, Trevi owes Keenova milestone payments upon completion of the first Phase 3 trial and U.S. marketing approval of a licensed product, plus royalties on any future net product sales. Manufacturing for clinical and, if approved, commercial supply depends on third-party contract manufacturers rather than in-house facilities.